Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, holds talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura (R) at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein, division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks with reporters after holding talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis Pharma

Novartis Pharma

TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.

Data altered in Japanese research for Novartis blood pressure drug

Data altered in Japanese research for Novartis blood pressure drug

TOKYO, Japan - Toshikazu Yoshikawa (2nd from L), president of the Kyoto Prefectural University of Medicine, and Shinji Fushiki (L), the university窶冱 vice president, bow toward the end of a press conference in Kyoto on July 11, 2013. Yoshikawa apologized as the university found that data employed in a clinical study on Novartis Pharama K.K.'s blockbuster blood pressure lowering drug Diovan were manipulated.